Abstract: An anti-Helicobacter pylori agent comprising a compound represented by the formula: wherein A represents an aromatic ring group which may be substituted; R1 and R2, whether identical or not, each represent a hydrogen atom or a hydrocarbon group which may be substituted; R3 and R4, whether identical or not, each represent a hydrogen atom, a hydrocarbon group which may be substituted, an acyl group, a carbamoyl group which may be substituted, or a carboxyl group which may be esterified; or a salt thereof.

Abstract: An anti-Helicobacter pylori agent comprising a compound represented by the formula: wherein A represents an aromatic ring group which may be substituted; R1 and R2, whether identical or not, each represent a hydrogen atom or a hydrocarbon group which may be substituted; R3 and R4, whether identical or not, each represent a hydrogen atom, a hydrocarbon group which may be substituted, an acyl group, a carbamoyl group which may be substituted, or a carboxyl group which may be esterified; or a salt thereof.

Abstract: A process for producing an optically active form of a compound of formula (I) ##STR1## wherein R.sub.1 represents hydrogen or a hydrocarbon group that may be substituted; R.sub.2 and R.sub.3 independently represent hydrogen, a hydrocarbon group that may be substituted, or a heteroaromatic group that may be substituted; X' represents a substituent comprising an esterified carboxyl group or an acylated hydroxyl group; ring A represents a benzene ring that may be substituted or a heteroaromatic ring that may be substituted; ring J' represents a 7- or 8-membered heterocyclic ring containing at most 3 hetero-atoms as ring-constituent members, which may have a further substituent or substituents in addition to R.sub.1, R.sub.2, R.sub.

Abstract: O-substituted fumagillol derivatives and its salts have an angiogenesis inhibiting activity and are useful for prophylaxis and treatment of diseases induced by abnormally stimulated neovascularization.

Abstract: A novel compound of the formula (I): ##STR1## wherein R.sub.1 is esterified carboxyl; R.sub.2, R.sub.3 and R.sub.4 are the same or different and are hydrogen or alkyl; A is formyl, hydroxyiminomethyl or carboxyl; and X is hydrogen or halogen, or a salt thereof, which is useful as an aromatase inhibitor or an intermediate of its production. Processes for producing the compound of the formula (I) and an aromatase inhibitor containing as an active component the compound of the formula (I) wherein A is formyl and X is hydrogen or, a salt thereof as well as Penicillium funiculosum capable for producing the compound (I) wherein R.sub.1 is carboxyl, R.sub.2, R.sub.3 and R.sub.4 are hydrogen and X is formyl are also disclosed.

Abstract: The present invention relates to a compound of the formula: ##STR1## wherein X is hydroxyl group or hydrogenatom, or a salt thereof. The compound (I) has an acitivity to inhibit angiogenesis, which is useful for prophylaxis and therapy of various diseases accompanying abnormally increased angiogenesis, especially of tumors.

Abstract: Dextran sulfate, .beta.-1,3-glucan sulfate, and the salts thereof are angiostatic and useful for treatment and prevention of various diseases caused by abnormally accelerated angiogenesis. Combination of such a compound with a steroidal or non-steroidal substance increases the angiostatic activity of each compound to induce the combined effect.

Abstract: Fumagillin and its salts have an angiogenesis inhibiting activity and are useful for prophylaxis and treatment of diseases induced by abnormally stimulated neovascularization. The invention also provides certain pharmaceutical compositions comprising fumagillin or its salt, and an agent which potentiates angiogenesis inhibition such as heparin and sulfated cyclodextrins such as beta-cyclodextrin tetradecasulfate.

Abstract: A novel compound of the formula (I): ##STR1## wherein R.sub.1 is optionally esterified or amidated carboxyl; R.sub.2, R.sub.3 and R.sub.4 are the same or different and are hydrogen or alkyl; A is formyl, hydroxyiminomethyl or carboxyl; and X is hydrogen or halogen, or a salt thereof, which is useful as an aromatase inhibitor or an intermediate of its production. Processes for producing the compound of the formula (I) and an aromatase inhibitor containing as an active component the compound of the formula (I) wherein A is formyl and X is hydrogen or, a salt thereof as well as Penicillium funiculosum capable for producing the compound (I) wherein R.sub.1 is carboxyl, R.sub.2, R.sub.3 and R.sub.4 are hydrogen and X is formyl are also disclosed.

Abstract: The present invention relates to an aromatase inhibiting composition which contains a compound of the formula: ##STR1## wherein R is hydroxy, lower alkoxy or amino which may be substituted by lower alkyl; R.sup.1 is hydrogen or lower alkyl; and A is hydrogen, a group of the formula ##STR2## in which R.sup.2 is hydroxy, lower alkoxy or amino which may be substituted by lower alkyl and R.sup.3 is hydrogen or lower alkyl, or a group of the formula ##STR3## in which R.sup.4 and R.sup.5 are independently hydrogen or lower alkyl, or a salt thereof.The present composition is useful in the prevention and treatment of estrogen-dependent diseases, such as breast cancer.

Abstract: A compound of the formula: wherein R.sub.1 is hydrogen, alkyl or acyl, R.sub.2 is hydroxy, alkoxy or amino, is useful as an antidiabetic agent.

Abstract: A novel compound of the formula (I): ##STR1## wherein R.sub.1 is optionally esterified or amidated carboxyl; R.sub.2, R.sub.3 and R.sub.4 are the same or different and are hydrogen or halogen or alkyl; A is formyl, hydroxyiminomethyl or carboxyl; and A is hydrogen or halogen, or a salt thereof, which is useful as an aromatase inhibitor or an intermediate of its production. Processes for producing the compound of the formula (I) and an aromatase inhibitor containing as an active compound the compound of the formula (I) wherein A is formyl and X is hydrogen or, a salt thereof as well as Penicillium funiculosum capable for producing the compound (I) wherein R.sub.1 is carboxyl, R.sub.2, R.sub.3 and R.sub.4 are hydrogen and X is formyl are also disclosed.

Abstract: The present invention relates to a compound FA-4283 or its derivative of the formula: ##STR1## wherein R is hydrogen or lower alkyl, and 3,4- and 3',4'-double bond may be saturated with hydrogens, and the method of production thereof.The compound (I) of the invention has an action of inhibiting fatty acid synthesis, thus being useful as an agent for prophylaxis and improvement of disorders of glucose and lipid methabolism.

Abstract: A compound of the formula: ##STR1## wherein R.sub.1 is hydrogen, alkyl or acyl, R.sub.2 is hydroxy, alkoxy or amino, is useful as an antidiabetic agent.

Abstract: Physiologically active substance FA-5859 and its deacetyl compound represented by the formula: ##STR1## wherein R.sub.1 is a hydrogen atom or an acetyl group, are produced by a cultivation of a microorganism of the genus Emericella or Aspergillus (compound wherein R.sub.1 is an acetyl group) or by a method of chemical synthesis (compound wherein R.sub.1 is a hydrogen atom or an acetyl group).Said compounds or a salt thereof have excellent fatty acid degradation inhibiting activity and is useful as an antidiabetic agent in mammalian animals or as a biochemical reagent for studies on fatty acid metabolism.

Abstract: An antifibrotic substance P-1894B is produced by cultivating a microorganism belonging to the genus Streptomyces and being capable of producing P-1894B in a culture medium to have Antifibrotic substance P-1894B elaborated and accumulated in the cultured broth and recovering the substance.P-1894B is effective for the prophylaxis or treatment of the fibrosis due to excessive collagen accumulation in mammal.

Abstract: Compounds of the formula ##STR1## wherein n is equal to zero or 1 and their physiologically acceptable salts are effective for the prophylaxis or treatment of the fibrosis due to excessive collagen accumulation in mammal.